Skip to main content
Equibles
EVFM logo

EVFM · Evofem Biosciences, Inc.

Track EVFM — free

Use EVFM with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about EVFM

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.01 +0.00 (+7.04%) At close · Aug 18
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has concluded that these circumstances and the uncertainties associated with the Company's ability to obtain additional equity or debt financing on terms that are favorable to the Company, or at all, and otherwise succeed in its future operations raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$940,963
Shares
132.53M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.01 Open$0.01 Day$0.01–0.01 52W close$0.01–0.02 Avg vol 30d179K Short int390 · 0.0% float · 1.0d Short vol24% Last earningsAug 4, 2022 DataMay 2023–Aug 2026 Filing10-Q · Aug 14

Raw chart and full-history price indicators begin at the captured split on May 18, 2023; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 14, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.2 · calm Equity put/call 0.65
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −13%
below
Price vs 50-day avg −6%
below
RSI (14) 49
neutral
MACD trend Negative
52-week position 16%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −5%
trailing
6-month return −16%
trailing
YTD return −24%
this year
Relative strength −26%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Accumulating
+1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.00% of float · ▼ -96.6% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1 holders — near 4-yr low, contrarian setup
Squeeze score 22
low risk · 0–100
Fundamentals
Fair
Revenue growth +104%
Y/Y
EPS growth +100%
Y/Y
Free cash flow $-2.0M
Balance sheet $9.4M
net debt
Quant / Vol
risk profile
Very High
Volatility 141%
annualized · 1-yr
Max drawdown −63%
past year
ATR 13.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−13% Bearish
Price vs 50-day avg
−6% Bearish
RSI (14)
49 Neutral
MACD trend
Negative Bearish
52-week position
16% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Accumulating
+1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.00% of float · ▼ -96.6% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1 holders — near 4-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0 Now $0 · 16% Range high $0
vs 200-day avg -13% vs 50-day avg -6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
EVFM
Evofem Biosciences, Inc.
this stock
$940,963 -24.0% +104.2% — 0.0%
ONC
BeOne Medicines Ltd.
 $535.83B +21.5% +22179.2% 823.9 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.88B +16.5% +46.2% 30.8 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $84.27B +5.0% +20.8% 20.3 3.3%
ARGX
Argenx SE
 $52.94B +18.1% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
1
% held
0.0%
Net QoQ
+1 sh
Top holder
BESSEMER GROUP INC
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
390
Days to cover
1.0d
Change
-10.9K sh
View
Short Volume
Short vol %
24%
As of
Aug 18, 2026
Short Total
View
Fails to Deliver
FTD shares
938
Value
$0
As of
Apr 2, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$20.2M
Net income (FY)
$391.0K
EPS diluted
$0.00
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 14, 2026
This year
11
View
Exempt Offerings
Offering
$925.0K
Filed
Jul 2, 2025
View
Earnings & Events
Earnings Calls
Last call
Aug 4, 2022
View
Investor Relations
Latest news
Evofem Reports Second Quarter 202…
Published
Aug 14, 2026
View

Performance

Raw-price comparisons begin at the captured split on May 18, 2023; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
EVFM -7.3% -5.0% -15.6% +8.6% -24.0%
SPY -0.4% +2.6% +10.7% +2.7% +12.5%
vs SPY -6.9% -7.6% -26.3% +5.8% -36.5%
Key facts CIK 1618835 CUSIP 30048L302 13F (30d) 1 filings 1 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)